Inactivation rates of <i>E</i>. <i>coli</i> bacteria retained on the surfaces of LEO-MWCNTs, TTO-MWCNTs, or Mix-MWCNTs filters with 10, 20 or 50 μL EO coatings. by Xiuli Dong (658906)

Subjects:

Half-maximal inhibitory concentration (IC₅₀), half-maximal cytotoxic concentration (CC₅₀), and selectivity index (SI) of CTLL formulation and its ingredients. by Prapaporn Chaniad (9761710)

Half-maximal inhibitory concentration (IC₅₀), half-maximal cytotoxic concentration (CC₅₀), and selectivity index (SI) of PSCD formulation and its ingredients. by Prapaporn Chaniad (9761710)

In house finch Harderian glands, we identified ˜90% fewer differentially expressed genes when comparing non-infected controls to MG-infected birds from populations that are more to... by Amberleigh E. Henschen (3257235)

Definitions of the features selected [50]. by Yu Zhang (12946)

Effect of Safr and Cands on the levels of complex I (U/mg protein), complex II (U/mg protein), complex IV (U/mg protein), caspase-3 (Casp-3, μg/mg protein), Fas ligand (FasL, μg/mg... by Nagwa Ibrahim Shehata (17319689)

Subjects:

Fig 2 - by Nida Mansoora (11648641)

Subjects:

Fig 3 - by Nida Mansoora (11648641)

Subjects:

Fig 4 - by Nida Mansoora (11648641)

Subjects:

Fig 1 - by Nida Mansoora (11648641)

Subjects:

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Gene specific primers used for <i>GmNN1/FT2a</i> fine mapping. by Xinxin Li (281237)